Results 41 to 50 of about 1,115 (163)

Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL-AVA 3.5 study. [PDF]

Br J Haematol
Summary Real‐world data on treatment response after switching between thrombopoietin receptor agonists are limited for patients with immune thrombocytopenia (ITP). The objective of this study is to describe treatment patterns and outcomes in patients with primary ITP who switched from eltrombopag (ELT) or romiplostim (ROMI) to avatrombopag (AVA).
Piatek C, Oladapo A, Kolodny S, Vredenburg M, Lucht S, Bland E, Pathak P, Feinberg B, Maitland H.   +8 more
europepmc   +2 more sources

Acquired Amegakaryocytic Thrombocytopenia With Evolution Toward Aplastic Anemia Treated With Thrombopoietin Receptor Agonists: A Case Report. [PDF]

Case Rep Med
Amegakaryocytic thrombocytopenia is a rare hematological disorder that is characterized by absent or near‐absent megakaryocytes without evidence of other hematological abnormalities. The disease can either be congenital or acquired. Given that less than a hundred cases of acquired amegakaryocytic thrombocytopenia (AAMT) have been reported in the ...
Jabbari-Zadeh F, Basharat MM, Chin-Yee B, Phua CW, Lam S, Xenocostas A, To E, Hsia CC.   +7 more
europepmc   +2 more sources

Clinical efficacy of avatrombopag and recombinant human thrombopoietin in the treatment of chronic liver disease-associated severe thrombocytopenia: A real-world study

Frontiers in Pharmacology, 2022
Purpose: To investigate the clinical efficacy of avatrombopag, an oral thrombopoietin receptor agonist, versus subcutaneous recombinant human thrombopoietin (rh-TPO) in the treatment of severe thrombocytopenia (TCP) associated with chronic liver disease (
Yong-Shuai Wang, Wei Wang, Sai Zhang, Shen-Yu Zhang, Ai-Zong Shen, Wei Wang, Hua-Chuan Song, Huan-Zhang Yao, Rui-Peng Song, Fan-Zheng Meng, Lei Li, Bjoern Nashan, Ji-Zhou Wang, Ji-Zhou Wang, Lian-Xin Liu, Lian-Xin Liu   +15 more
doaj   +1 more source

Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia : A Systematic Literature Review and Network Meta-Analysis [PDF]

, 2021
Introduction: A network meta-analysis (NMA) was performed to assess the efficacy and safety of avatrombopag, relative to eltrombopag, romiplostim, and fostamatinib, for patients with chronic immune thrombocytopenia (ITP) not responding adequately to ...
Vredenburg, Michael, Pustułka, Iwona, Wojciechowski, Piotr, Tytuła, Anna, Smela, Beata, Pochopien, Michał, Nazir, Jameel, Mccrae, Keith R., Wilson, Koo, Jurczak, Wojciech, Koo Wilson, Beata Smela, Wojciech Jurczak, Piotr Wojciechowski, Keith R. McCrae, Iwona Pustułka, Anna Tytuła, Jameel Nazir, Michał Pochopien, Michael Vredenburg   +19 more
core   +1 more source

Analysis of the Efficacy and Safety of Avatrombopag Combined With MSCs for the Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation

Frontiers in Immunology, 2022
Platelet graft failure (PGF) is a frequent and serious complication after Allogeneic hematopoietic stem cell transplantation (allo-HSCT) and lacks effective treatment strategies, which could affect the prognosis of patients and even cause death.
Lidan Zhu, Jia Liu, Peiyan Kong, Shichun Gao, Lu Wang, Huanfeng Liu, Cheng Zhang, Li Gao, Yimei Feng, Ting Chen, Lei Gao, Xi Zhang   +11 more
doaj   +1 more source

Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: a narrative review and an approach for managing patients fasting intermittently

Frontiers in Cardiovascular Medicine, 2023
IntroductionThrombopoietin-receptor agonist (TPO-RAs) currently represent the state of art for treating immune thrombocytopenia. Their different molecular structures contribute to the difference in their pharmacodynamics and pharmacokinetics.
Mohamed A. Yassin, Mona Al-Rasheed, Murtadha Al-Khaboori, Mahmoud Marashi, Hani Osman, Yasser Wali, Salam Al Kindi, Faisal Alsayegh, Drew Provan   +8 more
doaj   +1 more source

Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI) [PDF]

Avatrombopag is the newest thrombopoietin receptor agonist (TPO-RA) approved to treat immune thrombocytopenia (ITP). Real-world evidence regarding effectiveness/safety is limited.
Gil-Fernández, Juan José, Sánchez-González, Blanca, Pascual Izquierdo, Cristina, Menor-Gómez, María, Canaro-Hirnyk, Mariana Isabel, Mingot Castellano, María Eva, Spanish ITP Group (GEPTI) of the Spanish Society of Hematology and Hemotherapy (SEHH), García-Donas, Gloria, Monsalvo-Saornil, Silvia   +8 more
core   +3 more sources

Fostamatinib i avatrombopag per al tractament de la trombocitopènia immune [PDF]

, 2022
Trombocitopènia immune; Fostamatinib; AvatrombopagTrombocitopenia inmune; Fostamatinib; AvatrombopagImmune thrombocytopenia; Fostamatinib; AvatrombopagFostamatinib és un inhibidor de la tirosina-cinasa esplènica que redueix la destrucció de plaquetes ...
Programa d'Harmonització Farmacoterapèutica
core  

Avatrombopag [PDF]

Reactions Weekly, 2021
Meyer, Oliver, Ostermann, Helmut, Wörmann, Bernhard, Gesellschaft Für Thrombose- Und Hämostaseforschung, Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, Deutschland. Gemeinsamer Bundesausschuss, Matzdorff, Axel   +6 more
  +5 more sources

Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors: A multicenter, open-label, single-arm trial

Frontiers in Pharmacology, 2022
Objective: To explore the effect and safety of avatrombopag for chemotherapy-induced thrombocytopenia (CIT).Methods: This multicenter, open-label, single-arm trial enrolled CIT patients in eight centers from October 2020 to April 2021.
Yayun Cui, Yifu He, Changlu Hu, Congyin Tu, Jin Huang, Xiaofeng Zhu, Chunbao Zang, Kaiyang Ding, Bihong Zhan, Yufei Zhao, Liting Qian   +10 more
doaj   +1 more source